GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide)

Type: drug

Status: FDA Approved (for T2D and weight management)

Developer: Novo Nordisk

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026